327 related articles for article (PubMed ID: 2677243)
1. Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder.
Norman TR; Burrows GD
J Neural Transm Suppl; 1989; 28():53-63. PubMed ID: 2677243
[TBL] [Abstract][Full Text] [Related]
2. Studies of selective and reversible monoamine oxidase inhibitors.
Mann JJ; Aarons SF; Frances AJ; Brown RD
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
[TBL] [Abstract][Full Text] [Related]
3. Reversible monoamine oxidase-A inhibitors in panic disorder.
Bakish D; Saxena BM; Bowen R; D'Souza J
Clin Neuropharmacol; 1993; 16 Suppl 2():S77-82. PubMed ID: 8313401
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of MAO inhibitors: safety and future.
Yamada M; Yasuhara H
Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G
J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
[TBL] [Abstract][Full Text] [Related]
6. Reversible monoamine oxidase-A inhibitors in resistant major depression.
Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
8. Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.
Garcia-Borreguero D; Lauer CJ; Ozdaglar A; Wiedemann K; Holsboer F; Krieg JC
Pharmacopsychiatry; 1992 Nov; 25(6):261-4. PubMed ID: 1494591
[TBL] [Abstract][Full Text] [Related]
9. Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of panic disorder: brief review.
Liebowitz MR
Psychopharmacol Bull; 1989; 25(1):17-20. PubMed ID: 2672068
[No Abstract] [Full Text] [Related]
10. Monoamine oxidase inhibitors and alprazolam in the treatment of panic disorder and agoraphobia.
Sheehan DV
Psychiatr Clin North Am; 1985 Mar; 8(1):49-62. PubMed ID: 2859580
[TBL] [Abstract][Full Text] [Related]
11. Differential response patterns to MAO inhibitors and tricyclics.
Nies A
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):70-7. PubMed ID: 6376487
[TBL] [Abstract][Full Text] [Related]
12. Effects of some anxiogenic agents on rat brain monoamine oxidase (MAO) A and B inhibitory (tribulin) activity.
Bhattacharya SK; Chakrabarti A; Sandler M; Glover V
Indian J Exp Biol; 1996 Dec; 34(12):1190-3. PubMed ID: 9246908
[TBL] [Abstract][Full Text] [Related]
13. Tribulin and endogenous MAO-inhibitory regulation in vivo.
Medvedev AE; Glover V
Neurotoxicology; 2004 Jan; 25(1-2):185-92. PubMed ID: 14697893
[TBL] [Abstract][Full Text] [Related]
14. Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.
Chiuccariello L; Cooke RG; Miler L; Levitan RD; Baker GB; Kish SJ; Kolla NJ; Rusjan PM; Houle S; Wilson AA; Meyer JH
Int J Neuropsychopharmacol; 2015 Aug; 19(1):. PubMed ID: 26316187
[TBL] [Abstract][Full Text] [Related]
15. Selective monoamine uptake inhibitors and a serotonin antagonist in the treatment of panic disorder.
Westenberg HG; den Boer JA
Psychopharmacol Bull; 1989; 25(1):119-23. PubMed ID: 2528158
[No Abstract] [Full Text] [Related]
16. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
Naoi M; Riederer P; Maruyama W
J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
[TBL] [Abstract][Full Text] [Related]
17. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
Bainbridge JL; Page RL; Ruscin JM
Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
[TBL] [Abstract][Full Text] [Related]
18. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders.
Liebowitz MR; Hollander E; Schneier F; Campeas R; Welkowitz L; Hatterer J; Fallon B
Acta Psychiatr Scand Suppl; 1990; 360():29-34. PubMed ID: 2248064
[TBL] [Abstract][Full Text] [Related]
19. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
Magyar K; Szende B
Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
[TBL] [Abstract][Full Text] [Related]
20. Acute cardiovascular response to monoamine oxidase inhibitors: a prospective assessment.
Keck PE; Vuckovic A; Pope HG; Nierenberg AA; Gribble GW; White K
J Clin Psychopharmacol; 1989 Jun; 9(3):203-6. PubMed ID: 2738182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
